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SUMMARY
We assessed the clinical outcome of pregnancies with non-Rh-D antibody in Northern Ireland
using retrospective case note review.
During the study period (April 1999- March 2000) 186 women with clinically significant
antibodies were identified from the records ofthe antenatal laboratory ofthe Northern Ireland
Blood Transfusion Service. Eighty-five women were included in the study using the criteria
mentioned above. None ofthe fetuses required intrauterine transfusion during this period. One
babyrequiredexchangetransfusion,threeweregiventop-uptransfusionsand17hadphototherapy.
Nine babies with a positive direct antiglobulin test (DAT) received no treatment.
Theincidenceofanti-KellcouldbereducedbytransfusingKellnegativeredcellstopremenopausal
women. It is important that all pregnant women are tested at least twice in their pregnancy to
detect the antibodies formed late in the pregnancy. It is useful to formulate a standard protocol
for antenatal interventions. Non Rh-D antibodies can cause significant anaemia for up to six
weeks in the neonatal period, hence early detection ofmaternal antibodies is important so that
the neonates are followed up for an appropriate length of time.
INTRODUCTION
Although the prevalence of anti-D has
significantly declined inrelation to otherredcell
antibodies, anti-D still remains the major cause
of morbidity and mortality associated with
haemolytic disease of the newborn (HDN) and
the fetus. The fetal and neonatal outcomes of
anti-D affected pregnancies in Northern Ireland
have been reported recently2. This study was
undertakentoassessthemanagementandoutcome
ofpregnancies inwomenwhohadotherclinically
significant antibodies.
METHODS
The Northern Ireland BloodTransfusion Service
(NIBTS) provides centralised antibody testing
for most ofthe antenatal clinics in the Province.
Blood samples from pregnant women are tested
forABOandRh-Dgroupandscreenedforatypical
antibodies.Antibodyscreeningisperformedusing
solid phase methodology (capture R assay)
following the manufacturer's methods. The
specificity oftheantibodyisidentifiedbyfurther
testingofthosesamplesthatgivepositivereaction
on initial screening.
The antibodies are classified into three groups:
Group I: anti-D, anti-c, anti-Kell
Group II: anti-Fya, anti-Fyb, anti-Jka, anti-Jkb,
anti-C, anti-Ce, anti-e, anti-E, anti-Cw, anti- M,
anti-N, anti-S, anti-s, anti-LUa
Group III: anti-Lea, anti-Leb, anti-P1, anti-I, anti
HI, cold agglutinins, enzyme agglutinins
(clinically not significant)
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A sample is requested from her partner if a
woman has either a group I or group II antibody
in her plasma to assess the risk to the fetus. All
pregnant women with group I antibodies are
monitored monthly up to 28 weeks gestation and
everytwoweeksthereafter.Theintervaloffollow
up for group II antibodies depends on the initial
titre, subsequent rise in titre, and the antigen
status of the partner. All the others are tested at
least twice, once at booking and once between
28-32 weeks.
All the women who had group I (other than anti-
D) and women with group II antibodies with a
titre of 1/16 or above anytime during the
pregnancy were included in the study. The case
notes were examined after obtaining permission
from the obstetricians responsible for the care of
these women. The following details were
obtained: historyofbloodtransfusion, indication
for transfusion, previous obstetric history,
antenatal interventions (ifany), time ofdelivery,
baby'sbirthweight,bloodgroup,DAT,bilirubin,
haemoglobin and details of management.
RESULTS
NIBTStested34,913samplesbetweenApril 1999
and March 2000. During the study period 186
women were found to have non Rh-D clinically
significantantibodies. Theantibodyidentification
details are given in Table 1. 85 women fulfilled
the inclusion criteria described above (Table 2).
The antigen status of the partners are given in
figure 1. Tenwomencouldnotbefollowedupfor
the following reasons: seven case notes were not
available, one woman moved to England during
pregnancy, two women were tested only onceby
their general practitioners and no further
information was available.
Therewasadefinitivehistoryoftransfusionin46
(61.3%)women, andtheantibodywaspregnancy
induced(notpreviouslytransfused)in 10(13.3%)
women. Transfusion history was not recorded in
19 cases, but 7 of these women had antigen-
negative partners, indicating that the antibody
was most likely transfusion-induced. It was
difficulttoclassifytheremaining 12women (Fig
2). 36 (48%) women were transfused in one of
their previous pregnancies following primary
postpartum haemorrhage, retained placenta,
ruptured ectopic pregnancy or miscarriage; two
weretransfusedfollowingnon-obstetric surgery,
two following trauma, two had transfusion to
correct anaemia and the reason for transfusion
was not recorded for the remaining four women.
Previous obstetric history was noted in detail in
womenwhowereatriskofanaffectedinfanti.e.,
womenwithhomozygous/heterozygous partners
orwhosepartners werenottested. 22womenhad
a positive antibody screen in their previous
pregnancy/pregnancies and at least six of them
had previously affected babies treated with
phototherapy for neonatal jaundice or top-up
transfusions for anaemia. Amniocentesis was
TABLE 1:
Antibody specificities (other than anti-D) ofantenatal women tested during studyperiod
Rh Group (other than anti-D) Non Rh Group
Antibody specificity No Antibody specificity No
anti-c (alone) 12 anti-Kell (alone) + others 34
anti-c + others 11 anti-Kell + others 7
anti-C (alone) 2 anti-Fya (alone) 9
anti-C + others 5 anti-Fya+ others 2
anti-C (alone) 42 anti-S 6
anti-E + others 7 anti-s 3
anti-Cw 20 anti-Jka 6
Others(anti-M 13: anti-N 3: 20
anti-Bga 3: anti-Kpa 1)
TOTAL 99 TOTAL 87
Rh = Rhesus blood group system
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Fig 1. Autigen Status of Partners.
TABLE 2:
Number and specificity ofthe red cell
antibodies in the study group
Antibody specificity Number
anti-Kell 41
anti-c 23
anti-Fya 9
anti-E 6
others 6
(anti-Cw 2: anti-Jka 1: anti-s 1:
anti-e 1, anti-E + Jka 1
TOTAL 85
performed in one woman with anti-Kell in her
threepreviouspregnanciesandalsointhecurrent
pregnancy. Five women with anti-c also had a
history of amniocentesis in their previous
pregnancies.
Eleven women (excluding one who had
amniocentesis to assess riskofDown syndrome)
had invasive antenatal interventions in this
pregnancy. Awomanwithanti-Kelltitreof1/512
went into premature labour at 32 weeks after the
second amniocentesis and the baby required
exchange transfusion for neonatal jaundice.
Cordocentesis wasperformedinonewomanwith
anti-Kell and anti-Jka due to increase in titres.
ThefetuswastypedKell-negativeandJka-positive
andhencefurtherinterventionswerenotrequired.
The baby was DAT positive due to anti-Jka but
didnotrequiretreatment. Awomanwithanti-Fya
titre of 1/16 had an amniocentesis done but the
reason for this intervention could not be
ascertained from herrecords. Herprevious three
babiesweretreatedwithphototherapyforneonatal
jaundice and this infant was also treated with
phototherapy for 24 hours (cord bilirubin
56,umol/1).
The clinical outcome of the antibody-affected
pregnancies is shown in table 3.
During the study period there were no fetal or
neonatal deaths directly attributed to the red cell
allommunisationandnoneofthefetusesrequired
intrauterine transfusions. Among the 38 women
who had anti-Kell detected in their sera, for
whom case notes were available, only ten had
antigen-positive (heterozygous) partners. We
decided to include the women with negative
partners in the study group when we noted a
significant rise in titres (1/64 to 1/2048) in two
women. The increase in titres could have been
due to underlying systemic lupus erythematosus
(SLE) in one ofthem. Theresults were discussed
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Fig 2. History ofTransfusion.
with the women by their obstetricians and it was
decided not to do invasive antenatal
investigations. The two babies were DAT
negative. Similarly all the other babies born to
Kell-negative fathers were DAT negative as
expected (DAT was not done in one case).
In this study, 10 of the 17 babies who needed
phototherapy were born to mothers with anti-c
and two babies needed top-up transfusions. One
ofthese babies was noted to bejaundiced on the
day of birth and found to be DAT positive and
phototherapy was commenced. The mother was
tested only once during pregnancy. She had only
non-specific coldantibodies inthis sample. Anti-
c andanti-Jkaweredemonstratedinthepostnatal
maternal sample and the same antibodies were
eluted from the red cells ofher baby. The infant
needed top-up transfusion due to a fall in
haemoglobin level (from 12 g/dl on day-I to 6.7
g/dIonday-10).Thelateappearanceofantibodies
iswellrecognisedandthe"guidelinesforantibody
testing during pregnancy" 7 recommend testing
all pregnant women twice in pregnancy, once at
booking and once between 28-32 weeks to allow
detection of late appearance of clinically
significant antibodies.
DISCUSSION
Among the nonRh-D antibodies, anti-c andanti-
Kell are those most likely to cause severe HDN.
Antibodies like anti-Fya, anti-E, anti-Ce, anti-e
and anti-Jka have also the potential to cause
significant HDN7. Other antibodies may rarely
cause clinically relevant HDN.
Anti-Kell differs from other red cell antibodies
becausethematernalantibodytitresandamniotic
fluid spectrophotometric estimation usually do
not correlate with fetal anaemia3'4. Anti-Kell
antibodies cause fetal anaemiaby suppression of
erythropoiesis rather than red cell destruction5'6.
Amniocentesis remains useful for identification
of fetal Kell genotype by polymerase chain
reaction(PCR)6whenthefatherhasundetermined
orheterozygous Kell antigen status. PCR results
enable the clinician to exclude the mothers with
Kell negative babies from further invasive
interventions. Blood group genotyping was not
usedas adiagnostictoolinanyofthecasesinthis
series. It should be noted that 26/41 women with
anti-Kell had ahistory oftransfusion and further
10 had negative partners and hence the antibody
was mostlikelytobetransfusioninduced(Fig2).
Most ofthe transfusions were given forobstetric
causes. NIBTS has started routine phenotyping
of donor units for Kell and other Rh antigens in
addition to ABO and Rh D typing. Northern
Ireland has a population of 562,900 pre
menopausal (age 0-45) female subjects (source:
Department of Demography and Methodology,
NorthernIreland,April 1999) anditispractically
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TABLE 3:
Outcome ofPregnancies
anti-K anti-c anti-E anti-Fya others Total
DAT Negative 32a 5b,c 2 2d 2C 43
DAT Positive, 2 3 1 3 0 9
No treatment
Phototheraphy 1 10 1 3f 29 17
Top up Tx 0 2 1 0 0 3
ExchangeTx 1 0 0 0 0 1
Fetal loss 2h 0 0 0 0 2
<16 weeks
TOTAL 38 20 5 8 4 75
Figures include:
a: DAT not done in one baby, father Kell negative.
b: DAT negative, c positive.
c: DAT negative, c negative, father homozygous cc.
d: DAT negative, Fya positive.
e: father homozygous ss.
f: prophylactic phototherapy: DAT positive, Fya negative, ABO incompatability.
g: parents Cw negative, baby DAT positive, Cw positive, given prophylactic phototherapy.
h: cause for spontaneous abortion, one had antigen negative partner.
DAT = Direct Antiglobulin Test. Tx = Transfusion.
possible to provide Kell negative blood to those
female recipients (inthe absence ofanti-cellano)
without depleting the blood stocks. Ninety-one
percent ofthe population are Kell negative; 91%
of recipients will be Kell negative. NIBTS
currently provides an inventory ofKell negative
typedunitstoallhospitalbloodbanks.Thefemale
population, agedbirthto45, is not an intensively
transfusedgroupandtherewillbelittleimpacton
theKellnegativeinventorybecauseofthebalance
ofKellnegativetoKellpositiveinourpopulation.
Ideally all female recipients aged 0 to 45 should
be Kell typed and this will have to be done in
hospital blood banks because not all women
present as antenatalcases toNIBTS forantenatal
testing in the laboratory. Ifthis recommendation
is routinely implemented, the number of anti-
Kell antibodies in pregnancies should decline
slowly.
However, inthecase ofanti-c antibodies, 50% of
thewomen werenotpreviously transfusedinthis
study (Fig 2). Hence, provision of c-antigen
negativeredcellstoc-antigennegative recipients
would be expected to make less impact on the
number of cases affected with anti-c because
unlikeanti-Kell,mostofthepartnersarec-antigen
positive and induction of immunisation in
pregnancy can still occur. Furthermore, this will
alsoinvolveadditionaltestingofallRh-Dpositive
pregnantwomenfortheirc-antigenstatus.Bowell
et al 10 expressed a similar opinion after a
retrospective study of 177 women with anti-c
over an 8-yearperiod and concluded thatroutine
c-antigen typing of premenopausal women was
notjustifiable. Kozlowski eta19 pointed out that
50% ofthe women with anti-c in their study had
beentransfused(similartoourfigures)compared
to 5% in unselected antenatal population. Hence
they felt it was worthwhile to perform antenatal
c antigen typing ofall Rh D positive women and
provide antigen selected bloodto coverobstetric
emergencies.
There was no major institutional variation in the
care ofthe neonates as there is a uniform policy
among the neonatal units for the management of
neonataljaundice. All the babies were treated in
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accordance with the "guide charts for the
managementofhyperbilirubinaemia" whichgive
guidance for treatment for babies in different
birth weightranges. There areno specific British
Committee Standards in Haematology (BCSH)
guidelines related to management of
hyperbilirubinaemia in newborns. As partofany
investigationprotocolhoweverdirectantiglobulin
tests (DAT) shouldbeperformedonthebabyand
anantibodyscreenonmaternalplasmatoexclude
red cell allo antibodies as a cause of
hyperbilirubinaemia. Where the DAT is positive
and the maternal antibody screen is negative it is
necessary to perform a maternal v paternal
compatibility test to exclude private or low
incidence antigens as a cause of undetected
haemolytic disease ofthe newborn.
Theindicationsforantenatalinterventionsvaried
among different hospitals. Anti c antibody as
wellasgroupIIantibodiesdonotcausesignificant
HDN when detected below the titre of 1/327 and
hencemaybemonitoredbynon-invasivemethods.
NIBTS is planning to conduct a pilot study to do
quantitation ofanti-c toprovide assistance to the
obstetrician in decision-making. In a study
conducted in Manchester9, none of the babies
bornto mothers with anti-c levelbelow 9.5 iu/ml
required exchange transfusion. Based on this
observation, the authors suggested that invasive
antenatal interventionisnotnecessaryifthe anti-
c level is below 7.5 iu/ml, allowing for inherent
error in quantitation method.
This study highlights the fact that the clinical
outcome of non Rh-D antibodies affected
pregnancies is gooddue to careful monitoring of
pregnancy and effective neonatal care. Red cell
alloimmunisationremainsoneofthemajorcauses
of neonatal hyperbilirubinaemia resulting in
intensive neonatal care admission. Haemolysis
due to antibodies can continue to occur for up to
six weeks, andthe babies have to be followed up
duringthisperiodtodetectanaemia.Itisimportant
that laboratories undertaking antenatal testing
maintain an effective working relationship and
communication withthe midwives, obstetricians
and paediatricians to provide optimal perinatal
care for the patients.
C) The Ulster Medical Society, 2001
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